KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Ionis Pharmaceuticals (IONS) over the last 10 years, with Q4 2024 value amounting to $1.2 million.

  • Ionis Pharmaceuticals' Gains from Sales and Divestitures rose 1232.23% to $1.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.2 million, marking a year-over-year increase of 1232.23%. This contributed to the annual value of $1.2 million for FY2024, which is 1232.23% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $1.2 million for Q4 2024, which was up 1232.23% from $1.1 million recorded in Q4 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Gains from Sales and Divestitures peaked at $1.2 million during Q4 2024, and registered a low of $602000.0 during Q4 2020.
  • Its 5-year average for Gains from Sales and Divestitures is $926800.0, with a median of $958000.0 in 2022.
  • In the last 5 years, Ionis Pharmaceuticals' Gains from Sales and Divestitures surged by 4265.4% in 2020 and then soared by 1012.53% in 2023.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Gains from Sales and Divestitures stood at $602000.0 in 2020, then surged by 38.54% to $834000.0 in 2021, then increased by 14.87% to $958000.0 in 2022, then increased by 10.13% to $1.1 million in 2023, then increased by 12.32% to $1.2 million in 2024.
  • Its last three reported values are $1.2 million in Q4 2024, $1.1 million for Q4 2023, and $958000.0 during Q4 2022.